Global Animal Model Market was valued at US$ 1.91 Billion in 2022, growing at an estimated CAGR of 6.3% from 2023-2031.

An animal model is a living organism, typically an animal species like rodents, primates, or pigs, used in scientific research to study and understand biological processes, diseases, and human health. These models help researchers investigate complex biological mechanisms, test new therapies, and predict the potential effects of treatments before moving to human trials. By simulating physiological and genetic aspects of human conditions, animal models provide insights into disease progression, treatment responses, and safety assessments. Despite their utility, ethical concerns arise due to the use of animals in research. As such, scientists strive to develop alternatives like cell cultures and computer simulations. Animal models remain essential tools for advancing medical knowledge and improving human well-being while raising ethical questions that underline the need for responsible research practices. Among the animal types, mice and rats are typically the dominating and most commonly used species in scientific research due to their genetic similarity to humans and ease of handling. They constitute a substantial majority of animals used in research, with mice being particularly favored due to their short generation time and well-established genetic manipulation techniques.

Global Animal Model Market Revenue & Forecast, (US$ Million), 2015 – 2031

COVID-19 Impact Analysis on Global Animal Model Market

Pre-COVID-19, the animal model market was witnessing steady growth driven by pharmaceutical, biotechnology, and academic research. The demand for animal models, primarily mice and rats, was fueled by the need to understand diseases, develop therapies, and test drug efficacy. However, the pandemic introduced significant disruptions. Research activities were temporarily halted or redirected towards COVID-19 studies, diverting resources and attention. Despite this, the crisis also highlighted the importance of animal models in vaccine and drug development. Post-COVID-19, the market is adapting with renewed emphasis on infectious disease research. The accelerated vaccine development showcased the agility of animal models in testing treatments. While challenges remain, the pandemic reinforced the critical role of animal models in biomedical research, potentially leading to increased investments and advancements in the field.

Report Outline 

Advancements in genetic engineering have been a key driver of the animal model market. Techniques like CRISPR-Cas9 have revolutionized the creation of genetically modified animals for disease modeling, drug testing, and understanding gene function. For instance, a survey by the International Society for Transgenic Technologies reported that the use of CRISPR-Cas9 in creating animal models has rapidly increased since its inception, contributing to more accurate disease simulations. This trend enables researchers to develop models that closely mimic human conditions, enhancing the reliability of research outcomes and drug development. Ethical concerns surrounding animal welfare and increasing regulatory pressure have posed significant challenges to the animal model market. Public opinion on animal testing is evolving, and regulations are becoming more stringent. A study by Pew Research Center indicated that a considerable percentage of people expressed concerns about animal research. Additionally, governments and organizations are pushing for alternatives to animal models. The implementation of the 3Rs principle (Replacement, Reduction, Refinement) is gaining traction, urging researchers to seek alternatives, reduce animal use, and refine experimental techniques. These factors create a delicate balance between scientific progress and ethical considerations in the animal model industry.

In the global animal model market, pharma and biotech companies have established dominance and are experiencing faster growth compared to academic research institutes. Pharma and biotech companies heavily rely on animal models to conduct preclinical trials and test the safety and efficacy of potential drug candidates. According to a study published in the journal “Nature Reviews Drug Discovery,” the use of animal models in drug development has significantly contributed to successful clinical trials. This demand has led to a substantial investment in animal models by these companies.

North America conquered major market share in the global animal model market in 2022 due to the concentration of major pharmaceutical and biotechnology firms. The US National Institutes of Health (NIH) reported that the demand for animal models remains high for drug development and disease research in this region.

Competitive Landscape

The report provides both, qualitative and quantitative research of global animal model market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the players operating in the global animal model market are

• Charles River Laboratories
• Crown Bioscience
• genOway
• Hera Biolabs
• Inotiv
• Janvier Labs
• Ozgene Pty Ltd.
• Taconic Biosciences, Inc.
• The Jackson Laboratory
• Trans Genic Inc.
• Other Industry Participants

Global Animal Model Market Summary

Global Animal Model Market

By Animal Type

• Mice
• Rats
• Fish
• Birds
• Cattle
• Pigs
• Amphibians
• Guinea Pigs
• Dogs
• Cats
• Rabbits
• Monkeys
• Sheep
• Hamsters
• Other animal types

By Technology

• CRISPR
• Microinjection
• Embryonic Stem Cell Injection
• Nuclear Transfer
• Other technologies

By Application

• Drug Discovery and Development
• Basic Research
• Others

By End User

• Pharma and Biotech Companies
• Academic Research Institutes
• CROs and CDMOs

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

.

Table of Contents

.